BIONET Therapeutics Corp. (TPEX:7808)

Taiwan flag Taiwan · Delayed Price · Currency is TWD
40.50
-0.50 (-1.22%)
At close: May 7, 2026
Market Cap2.81B -7.1%
Revenue (ttm)154.48M +90.0%
Net Income-97.43M
EPS-1.39
Shares Out70.00M
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume73,420
Average Volume32,710
Open40.05
Previous Close41.00
Day's Range39.40 - 41.40
52-Week Range39.40 - 66.30
Betan/a
RSI22.56
Earnings DateMay 13, 2026

About BIONET Therapeutics

BIONET Therapeutics Corp., a biopharmaceutical company, develops cell therapy products and drug development for acute and severe diseases. The company develops treatment for adult respiratory distress syndrome, pulmonary fibrosis, chronic kidney disease, acute wound healing, chronic wound healing of diabetic ulcers, and osteoarthritis. It also provides CRDMO services. The company was founded in 2022 and is based in Taipei, Taiwan. [Read more]

Industry Biological Products, Except Diagnostic Substances
Founded 2022
Employees 105
Stock Exchange Taipei Exchange
Ticker Symbol 7808
Full Company Profile

Financial Performance

In 2025, BIONET Therapeutics's revenue was 154.48 million, an increase of 89.97% compared to the previous year's 81.32 million. Losses were -97.43 million, 12.9% more than in 2024.

Financial Statements